Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
182.32
+1.70 (0.94%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Revenue
In the year 2025, Jazz Pharmaceuticals had annual revenue of $4.27B with 4.88% growth. Jazz Pharmaceuticals had revenue of $1.20B in the quarter ending December 31, 2025, with 10.09% growth.
Revenue (ttm)
$4.27B
Revenue Growth
+4.88%
P/S Ratio
2.63
Revenue / Employee
$1,476,673
Employees
2,890
Market Cap
11.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.27B | 198.64M | 4.88% |
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| BridgeBio Pharma | 502.08M |
| ImmunityBio | 113.29M |
JAZZ News
- 6 days ago - Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PRNewsWire
- 11 days ago - Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential - FXEmpire
- 11 days ago - Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 25 days ago - Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook - Seeking Alpha
- 27 days ago - Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PRNewsWire